CHE Financials Chemed Corp

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated 29 h ago Overview →

Growth & profitability

Revenue has grown 4.0% per year over the past 5 years.
Net income has grown slower than revenue (-75.8% vs 4.0% per year).
Operating margin has contracted, at 13.4% in the latest year.
Free cash flow has declined 5.4% per year over the past 5 years.

Financial health

Total debt has grown slower than revenue (-0.7% vs 4.0% per year).
Operating income covered interest expense 193× in the latest year, up from 165× 5 years ago.

Shareholder returns

Dividends have been paid for 15 consecutive years, consuming 11949.6% of earnings and 9.7% of free cash flow.
The dividend has grown 8.5% per year over the past 5 years.

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Free cash flow (CFO − capex)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key annual figures

FY	Revenue	Net income	Gross M	Op M	FCF	Total debt	Cash
2025	$2.5B	$265238	32.5%	13.4%	$325M	—	$75M
2024	$2.4B	$301999	35.1%	15.1%	$368M	—	$178M
2023	$2.3B	$272509	35.3%	15.0%	$273M	—	$264M
2022	$2.1B	$249624	35.8%	16.1%	$253M	$98M	$74M
2021	$2.1B	$268550	36.0%	16.0%	$250M	$185M	$33M
2020	$2.1B	$319M	33.7%	18.7%	$430M	—	$163M
2019	$1.9B	$220M	31.8%	13.3%	$248M	$90M	$6M
2018	$1.8B	$206M	31.1%	13.7%	$234M	$89M	$5M
2017	$1.7B	$98M	31.0%	6.8%	$98M	$101M	$11M
2016	$1.6B	$109M	29.3%	11.3%	$96M	$109M	$15M
2015	—	$110M	—	—	$127M	$91M	$15M
2014	—	$99M	—	—	—	$148M	$14M
2013	—	$77M	—	—	—	$184M	$84M
2012	—	$89M	—	—	$97M	$175M	$70M
2011	—	$86M	—	—	$145M	$167M	$38M

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Free cash flow (CFO − capex, quarterly)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key quarterly figures

Quarter	Revenue	Net income	Gross M	Op M	FCF	Total debt	Cash
Mar '26	$658M	$66M	32.8%	12.9%	$71M	$91M	$17M
Dec '25	$639M	$77M	35.2%	15.7%	$117M	—	$75M
Sep '25	$625M	$64M	31.5%	12.0%	$66M	—	$130M
Jun '25	$619M	$52M	29.8%	11.0%	$123M	—	$250M
Mar '25	$647M	$72M	33.5%	14.6%	$19M	—	$174M
Dec '24	$640M	$90M	36.6%	17.8%	$152M	—	$178M
Sep '24	$606M	$76M	34.6%	15.2%	$77M	—	$238M
Jun '24	$596M	$71M	34.6%	14.8%	$66M	—	$223M
Mar '24	$589M	$65M	34.6%	12.3%	$72M	—	$313M
Dec '23	$586M	$90M	38.8%	19.0%	$97M	—	$264M
Sep '23	$565M	$75M	35.8%	15.4%	$17M	—	$173M
Jun '23	$554M	$53M	32.4%	12.6%	$116M	—	$160M
Mar '23	$560M	$54M	33.8%	13.0%	$43M	$21M	$58M
Dec '22	$547M	$62M	36.1%	14.9%	$82M	$98M	$74M
Sep '22	$526M	$57M	34.1%	15.4%	$39M	$101M	$8M
Jun '22	$531M	$66M	36.6%	17.3%	$44M	$117M	$10M
Mar '22	$531M	$64M	36.6%	16.8%	$88M	$120M	$18M
Dec '21	$541M	$75M	37.8%	18.1%	$49M	$185M	$33M
Sep '21	$539M	$72M	36.5%	17.2%	$102M	—	$29M
Jun '21	$532M	$57M	34.1%	13.5%	$9M	—	$92M

Valuation over time

How the market has priced CHE against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

The price-to-earnings ratio has fallen from 28642.4× (Mar '23) to 22690.1× (Jun '26).
The price-to-sales ratio has fallen from 3.3× (Mar '23) to 2.4× (Jun '26).
The dividend yield has risen from 0.3% (Mar '23) to 0.5% (Jun '26).

Price / earnings (P/E)

P/E

Price / sales (P/S)

P/S

Dividend yield (%)

Dividend yield %

Frequently asked questions

Is CHE growing its revenue and profit?

Over the past 5 years, Chemed Corp's revenue has grown 4.0% per year, and net income declined 75.8% per year. These are computed facts, not advice.

How much debt does CHE have?

As of FY2025, Chemed Corp reported — of total debt against $75M of cash; operating income covered interest expense 193×.

What is CHE's profit margin?

In FY2025, gross margin was 32.5%, operating margin 13.4%, and net margin 0.0%.

What is CHE's P/E ratio?

As of Jun '26, Chemed Corp traded at a price-to-earnings ratio of about 22690.1× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.